Are you one among the people who think that the cancer medication is just based on the cancer location or stage? That’s not exactly how it works. There are a lot of parameters that an oncologist should rule out. Below are the sequence of events that has to be undergone by a patient to come to a conclusion on when vemurafenib should be considered.
Step 1: Find the BRAF Signal
BRAF is a gene that plays a significant role in signaling pathways in cell growth. Some mutations create issues with gene expression and help in cancer growth. The primary function of vemurafenib is to inhibit BRAF kinase activity with V600 mutation. This is the reason why biomarker testing matters to understand the BRAF status and to confirm if it falls under the category to treat the type of melanoma you are suffering from.
Step 2: Ask, What Type of Cancer Are We Treating?
FDA approved the two indications for vemurafenib are as follows:
- Melanoma with BRAF V600 mutation :
– That cannot be removed by surgery
– That has already been spread to other regions of the body. - Erdheim-Chester disease (ECD) with BRAF V600 mutation.
Step 3: Check if the Treatment Is a Right Option for the Patient?
- Oncologists decide the treatment plan and recommend the medicine based on overall health status, past medical history, past treatments, risk factors, other medications usage and goals of care.
- The correct FDA-recommended dosage of vemurafenib is 960 mg twice daily, taken approximately12 hours apart, with or without food.
Step 4: Look for Skin Changes
- There is a higher possibility of affecting cutaneous squamous cell carcinoma in patients taking vemurafenib.
- Perform dermatologic evaluations prior to initiation of therapy and every 2 months while on therapy. Manage suspicious skin lesions with excision and dermatopathologic evaluation. Consider dermatologic monitoring for 6 months following discontinuation of vemurafenib.
- Vemurafenib is not for patients with severe dermatologic reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
- So the dermatological aspect of the patient becomes a part of decision making.
Step 5: What Does the Heart Say?
- Oncologist checks for cardiac status before the initiation of the treatment because vemurafenib can cause QT prolongation that may lead to an increased risk of ventricular arrhythmias, including Torsade de Pointes.
- Evaluate ECG and electrolytes (Potassium, magnesium and calcium) before and during treatment.
- Do not start treatment in patients with uncorrectable electrolyte abnormalities, QTc > 500 ms, or long QT syndrome, or in patients who are taking medicinal products known to prolong the QT interval.
Step 6: Make a Note of Liver Changes
- Evaluating liver health is important because vemurafenib can cause hepatotoxicity.
- Monitor liver enzymes before the initiation of the treatment and monthly during treatment.
Step 7: Does Sun Have Any Impact on the Patient?
- Ask the patient about issues with sun exposure. Photosensitivity is commonly encountered by patients receiving vemurafenib. It is advised to avoid sun exposure, wear protective clothing and use a broad spectrum UVA/UVB sunscreen and lip balm (SPF ≥ 30) when outdoors.
Step 8: Review All the Current Medications
- Your oncologist avoids the medications that cause hindrance in treatment outcomes.
- Avoid coadministration of vemurafenib with strong CYP3A4 inhibitors, strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin) and P-gp substrates known to have narrow therapeutic indices. If it’s unavoidable to use these medications, make dose modifications of vemurafenib.
Step 9: When Should Vemurafenib Not Be Considered as an Option?
Use of vemurafenib is not indicated in wild-type BRAF melanoma as it can promote cell proliferation through pathway effects.
Your oncologist considers several clinical factors before deciding whether prescribing vemurafenib is the appropriate next step. Get in touch with the 24/7QualityMeds at +91 9967979080 or share your prescription for information on advanced cancer therapies, vemurafenib price in India or how to buy vemurafenib online.
